Healthcare Sales & Marketing Network News: Diabetic Ketoacidosis

Searching News Database: Diabetic Ketoacidosis

HSMN NewsFeed - 6 Apr 2026
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 4 Oct 2024
Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life
Devices Drug Delivery Product Recall

HSMN NewsFeed - 26 Mar 2021
European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 11 Dec 2020
BAVENCIO(R) (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 31 Aug 2020
Mylan and Biocon Biologics Announce Launch of Semglee(TM) (insulin glargine injection) in the U.S. to Expand Access for Patients Living with Diabetes
Biopharmaceuticals Generics Product Launch

HSMN NewsFeed - 30 Jul 2020
Jardiance(R) meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in phase III trial in adults with and without diabetes
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 9 Apr 2020
EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO(R) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 13 Mar 2020
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Feb 2020
Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for PADCEV(TM) (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 20 Sep 2019
CHMP Issues Positive Opinion to Expand Trulicity(R) (dulaglutide) Label to Include Results from REWIND Cardiovascular Outcomes Trial
Biopharmaceuticals Endocrinology Cardiology Regulatory

HSMN NewsFeed - 5 Aug 2019
Instrumentation Laboratory Presents New GEM Premier ChemSTAT(TM) Testing System With iQM(R) At American Association For Clinical Chemistry Annual Meeting
Diagnostics Product Launch

HSMN NewsFeed - 26 Jun 2019
U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 14 Feb 2019
Boehringer Ingelheim and Lilly announce the CAROLINA(R) cardiovascular outcome trial of Tradjenta(R) met its primary endpoint of non-inferiority compared with glimepiride
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 19 Nov 2018
Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 Oct 2018
U.S. FDA Approves INVOKANA(R) (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease
Biopharmaceuticals Endocrinology Cardiology FDA

HSMN NewsFeed - 4 Oct 2018
Boehringer Ingelheim and Lilly present full results from EASE Phase III program for empagliflozin as adjunct to insulin in type 1 diabetes
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 27 Mar 2018
FDA approves Toujeo(R) Max SoloStar(R)
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 26 Mar 2018
FDA approves inclusion of data from safety outcomes trial in the Tresiba(R) label
Biopharmaceuticals Endocrinology Cardiology FDA

HSMN NewsFeed - 26 Feb 2018
New Data Show Lilly's Trulicity(R) (dulaglutide) in Combination with an SGLT-2 Inhibitor Improves Blood Sugar Control in People with Type 2 Diabetes
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 10 Jan 2018
BYDUREON(R) BCise(TM) Injectable Medicine Now Available In The US For Patients With Type-2 Diabetes
Biopharmaceuticals Endocrinology Product Launch

HSMN NewsFeed - 5 Dec 2017
INVOKANA(R) (canagliflozin) Significantly Improved Renal Outcomes and Demonstrated Potential Renal Protective Effects in Patients with Type 2 Diabetes Who Have or Are at Risk for Cardiovascular Disease
Biopharmaceuticals Nephrology

HSMN NewsFeed - 21 Sep 2017
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 15 Aug 2017
Lexicon Pharmaceuticals Reports Additional Positive Data From Pivotal Phase 3 inTandem2 Study Of Sotagliflozin
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 21 Jul 2017
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 9 Jun 2017
Lexicon Pharmaceuticals Reports Positive Top-Line Results In Phase 3 inTandem3 Study For Sotagliflozin In Patients With Type 1 Diabetes
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 9 May 2017
FDA Grants BAVENCIO(R) (avelumab) Approval for a Common Type of Advanced Bladder Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 24 Mar 2017
FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology FDA Product Launch

HSMN NewsFeed - 15 Mar 2017
FDA Approves Merck’s KEYTRUDA(R) (pembrolizumab) for Adult and Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refractory to Treatment, or Who Have Relapsed After Three or More Prior Lines of Therapy
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 14 Oct 2016
Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 21 Sep 2016
U.S. FDA Approves INVOKAMET(R) XR (Canagliflozin / Metformin Hydrochloride Extended-Release) for the Treatment of Adults with Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA

HSMN NewsFeed - 31 Aug 2016
XALKORI(R) (Crizotinib) Receives Approval In European Union For The Treatment Of Patients With ROS1-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 29 Jun 2016
FDA Advisory Committee recommends approval of Jardiance(R) (empagliflozin) for cardiovascular indication in 12-11 vote
Biopharmaceuticals Endocrinology Cardiology FDA

HSMN NewsFeed - 27 Jun 2016
Merck Receives CHMP Positive Opinion for KEYTRUDA(R) (pembrolizumab) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 16 Jun 2016
Merck’s KEYTRUDA(R) (pembrolizumab) Demonstrates Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Jan 2016
Novo Nordisk Launches Tresiba(R) (insulin degludec injection 200 Units/mL) in the United States
Biopharmaceuticals Endocrinology Product Launch

HSMN NewsFeed - 10 Dec 2015
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 Nov 2015
Pfizer Receives European Approval to Expand Use of XALKORI(R) (crizotinib) to First-Line Treatment of Adults with ALK-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 24 Nov 2015
European Commission Approves Reconciliation of Indications for nivolumab Under the Opdivo(R) European Marketing Authorization Application
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 24 Nov 2015
Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 18 Nov 2015
Pfizer Reports Positive Topline Results from Phase 3 Trial Comparing XALKORI(R) (crizotinib) to Chemotherapy in Previously Untreated East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Oct 2015
Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for the Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen in BRAF V600 Wild-Type Unresectable or Metastatic Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 20 Aug 2015
Jardiance(R) Demonstrated Cardiovascular (CV) Risk Reduction in People with Type 2 Diabetes at High Risk for CV Events
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 24 Apr 2015
Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Opdivo (nivolumab) for the Treatment of Advanced Melanoma in Both First-Line and Previously Treated Patients
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 30 Oct 2014
U.S. FDA Approves Once-Daily XIGDUO(TM) XR Tablets for Adults with Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA

HSMN NewsFeed - 11 Aug 2014
Sanofi and MannKind Announce Global Licensing Agreement for Afrezza(R) (insulin human) Rapid-Acting Inhaled Insulin
Biopharmaceuticals Endocrinology Drug Delivery Licensing

HSMN NewsFeed - 8 Apr 2014
Takeda Responds to Verdict in Diabetes Drug Case
Biopharmaceuticals Endocrinology Litigation

HSMN NewsFeed - 3 Mar 2014
U.S. FDA Approves Bydureon(R) Pen (exenatide extended-release for injectable suspension) for Once-Weekly Treatment of Adults with Type 2 Diabetes
Biopharmaceuticals Drug Delivery Endocrinology FDA

HSMN NewsFeed - 13 Jan 2014
U.S. FDA Approves Farxiga(TM) (Dapagliflozin) Tablets for the Treatment of Adult Patients with Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA

HSMN NewsFeed - 25 Sep 2013
Par Pharmaceutical Begins Shipment of Generic Glucotrol XL(R)
Biopharmaceuticals Generics FDA Product Launch

HSMN NewsFeed - 19 Jun 2013
AstraZeneca and Bristol-Myers Squibb Announce Top Line Results for SAVOR-TIMI-53 Cardiovascular Outcomes Trial of Onglyza(R) (saxagliptin)
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 29 Apr 2013
Merck & Co., Inc. and Pfizer Enter Worldwide Collaboration Agreement to Develop and Commercialize Ertugliflozin, an Investigational Medicine for Type 2 Diabetes
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 22 May 2012
FDA Approves Levemir(R) for Expanded Use in Children Two to Five Years of Age with Type 1 Diabetes
Biopharmaceuticals Endocrinology FDA

HSMN NewsFeed - 2 Apr 2012
FDA Approves Levemir(R) Pregnancy Category Change for Women with Diabetes
Biopharmaceuticals Endocrinology FDA

HSMN NewsFeed - 23 Mar 2012
BYETTA(R) Approved for Use with Basal Insulin in Europe
Biopharmaceuticals Endocrinology Regulatory

HSMN NewsFeed - 8 Nov 2011
Lilly and Amylin Mutually Agree to End Diabetes Alliance and Transition Exenatide Responsibility to Amylin
Biopharmaceuticals

HSMN NewsFeed - 21 Jun 2011
Bydureon Receives Marketing Authorization in Europe
Biopharmaceuticals Endocrinology Regulatory

HSMN NewsFeed - 16 May 2011
Lilly Provides Its Perspective in Response to Amylin Lawsuit
Biopharmaceuticals Litigation

HSMN NewsFeed - 16 May 2011
Lilly Provides Statement in Response to Amylin Lawsuit
Biopharmaceuticals Litigation

HSMN NewsFeed - 16 May 2011
Amylin Pharmaceuticals Files Suit Against Eli Lilly
Biopharmaceuticals Litigation

HSMN NewsFeed - 21 Apr 2011
Novo Nordisk Announces U.S. Launch of NovoTwist(R) for Use with Levemir(R) FlexPen(R), NovoLog(R) FlexPen(R) and Victoza(R) Pen Devices
Devices Drug Delivery Endocrinology

HSMN NewsFeed - 15 Apr 2011
BYDUREON Recommended for Approval in Europe
Biopharmaceuticals Endocrinology Regulatory

HSMN NewsFeed - 15 Nov 2010
Santarus Announces Commercial Launch of Novel Type 2 Diabetes Drug CYCLOSET
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 23 Sep 2010
Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S.
Biopharmaceuticals Endocrinology Regulatory

HSMN NewsFeed - 28 Apr 2010
Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S.
Biopharmaceuticals Litigation Endocrinology

HSMN NewsFeed - 15 Mar 2010
Amylin, Lilly and Alkermes Receive Complete Response Letter From FDA for Exenatide Once Weekly Submission
Biopharmaceuticals

HSMN NewsFeed - 9 Mar 2010
Bristol-Myers Squibb and AstraZeneca Announce the Commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Trial (SAVOR-TIMI 53)
Biopharmaceuticals Cardiology Endocrinology

HSMN NewsFeed - 26 Jan 2010
Novo Nordisk's Victoza(R) Receives FDA Approval for Adults With Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA

HSMN NewsFeed - 28 Sep 2009
MSD Receives Positive CHMP Opinion for 'Januvia(R)' and 'Janumet(R)' as Add-On to Insulin in the European Union
Biopharmaceuticals Endocrinology Regulatory

HSMN NewsFeed - 22 Jul 2008
Santarus and Depomed Announce U.S. Promotion Agreement for GLUMETZA Prescription Products
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 24 Jun 2008
FDA Approves PrandiMet(TM), a Replaglinide and Metformin Fixed-Dose Combination Tablet for Treatment of Type 2 Diabetes
Biopharmaceuticals FDA Endocrinology

HSMN NewsFeed - 16 May 2008
Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 24 Apr 2008
Two Merck Medicines Recommended for Approval in the European Union
Biopharmaceuticals Regulatory

HSMN NewsFeed - 21 Jan 2008
Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults With Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA

HSMN NewsFeed - 19 Jan 2008
Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA

HSMN NewsFeed - 2 Jan 2008
Depomed Receives FDA Approval for 1000 mg Strength Tablets of Glumetza
Biopharmaceuticals FDA Endocrinology Drug Delivery

HSMN NewsFeed - 19 Nov 2007
Novo Nordisk Inc. Announces Exclusive Agreement With Sciele Pharma, Inc. to Market Prandin(R)
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 29 Oct 2007
Depomed and King Pharmaceuticals Terminate Promotion Agreement for GLUMETZA(TM)
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 17 Oct 2007
FDA Approves Supplemental New Drug Applications for JANUVIA(TM) (sitagliptin)
Biopharmaceuticals Endocrinology FDA

HSMN NewsFeed - 18 Sep 2007
One-Year Data Showed Investigational Use of Initial Combination Therapy with JANUVIA(TM) (sitagliptin) and Metformin Significantly Improved Blood Sugar Control in Patients with Type 2 Diabetes Compared to Metformin Alone
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 25 Jun 2007
New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir(R)
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 30 May 2007
Data Affirms Avandia (Rosiglitazone maleate) Cardiovascular Safety Profile
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 2 Apr 2007
FDA Approves JANUMET(TM) for Type 2 Diabetes, Offering Powerful Glucose Control of a DPP-4 Inhibitor and Metformin in a Single Tablet
Biopharmaceuticals FDA Endocrinology

HSMN NewsFeed - 2 Apr 2007
Depomed Files Prior Approval Supplement for 1000 mg Strength Tablets of Glumetza
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 15 Feb 2007
FDA Accepts Two Supplemental New Drug Applications to Expand the U.S. Labeling for JANUVIA(TM)
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 21 Dec 2006
Eli Lilly and Company Statement Regarding Today's New York Times Article - December 21, 2006
Biopharmaceuticals

HSMN NewsFeed - 1 Dec 2006
Merck Announces JANUMET(TM), the Trademark for its Investigational Combination Therapy of Sitagliptin Phosphate and Metformin for Type 2 Diabetes
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 17 Oct 2006
FDA Approves Once-Daily JANUVIA(TM), the First and Only DPP-4 Inhibitor Available in the United States for Type 2 Diabetes
Biopharmaceuticals FDA Endocrinology

HSMN NewsFeed - 13 Sep 2006
One in Three Parents Surveyed Unaware of Easy Ketone Test That May Help Prevent the Onset of Diabetic Ketoacidosis (DKA)
Diagnostics Endocrinology

HSMN NewsFeed - 28 Jun 2006
King Pharmaceuticals and Depomed Announce Agreement to Co-Promote Glumetza(TM)
Biopharmaceuticals Endocrinology

Return to NewsFeed

Additional items found! 16

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 16 additional stories matching:
Diabetic Ketoacidosis
(Password required)

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!